查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1565660

口服抗病毒市场，按类型、给药途径、应用、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Oral Antiviral Market, By Type, By Route of Administration, By Application, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年口服抗病毒药物市场规模为379.0432亿美元，2024年至2032年复合年增长率为2.90%。

口服抗病毒药物市场-市场动态

病毒性疾病盛行率的增加促进了口服抗病毒药物市场的成长

病毒性疾病的日益流行极大地推动了口服抗病毒药物市场的成长。据世界卫生组织 (WHO) 称，流感和 COVID-19 仍然是全球主要的健康问题，每年有数百万人受到影响。美国疾病管制与预防中心 (CDC) 报告称，在 COVID-19 大流行期间，抗病毒处方数量激增，凸显了口服抗病毒药物在管理广泛感染方面的关键作用。例如，Paxlovid 是一种治疗 COVID-19 的口服抗病毒药物，在上市第一年就为超过 50 万名患者开了处方。此外，单纯疱疹等慢性病毒性疾病的增加增加了对有效口服治疗的需求。随着全球对抗病毒性疾病的关注不断加强，抗病毒药物开发的进步和扩大这些药物的使用范围是推动市场成长的关键因素。

口服抗病毒药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 2.90% 左右的复合年增长率成长

根据类型细分，预计核苷类似物将在 2023 年显示最大的市场份额

根据给药途径细分，平板电脑是 2023 年的主导类型

根据应用细分，COVID-19 是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

口服抗病毒药物市场-細項分析：

全球口服抗病毒药物市场根据类型、给药途径、应用、最终用户和地区进行细分。

市场依类型分为四大类：核苷类似物、蛋白酶抑制剂、神经氨酸酶抑制剂和聚合酶抑制剂。核苷类似物因其对各种病毒感染的广泛功效而引领市场。随后是蛋白酶抑制剂，针对特定病毒提供针对性的作用。神经氨酸酶抑制剂对于流感治疗很重要，而聚合酶抑制剂也很重要，但不太常用。

根据给药途径，市场分为三类：药片、胶囊和口服混悬剂。片剂因其便利性和剂量准确性而成为最受欢迎的给药途径。胶囊紧随其后，以不同的形式提供类似的好处。口服混悬液的使用频率较低，但对于吞嚥药片或胶囊有困难的患者很有价值。

口服抗病毒药物市场 - 地理洞察

口服抗病毒药物市场表现出明显的地区差异，其中北美由于先进的医疗保健系统和高药物采用率而处于领先地位。在美国，FDA 在 COVID-19 大流行期间迅速批准了 Paxlovid 等口服抗病毒药物，导致其广泛使用，第一年就服用了超过 1000 万剂。欧洲紧随其后，英国和德国等国家实施了全面的抗病毒治疗计划，显着增加了市场需求。欧洲药品管理局 (EMA) 透过快速批准新的抗病毒药物来支持这一成长。在亚太地区，由于病毒感染率上升和医疗保健投资增加，日本和印度等国家正在经历快速的市场扩张。例如，日本卫生部提倡使用口服抗病毒药物来控制流感疫情。在医疗基础设施不断完善和抗病毒治疗意识不断提高的推动下，拉丁美洲、中东和非洲也是不断增长的市场。

口服抗病毒药物市场-竞争格局：

口服抗病毒药物市场竞争激烈，主要参与者积极参与策略性措施以维持其市场地位。领先企业辉瑞 (Pfizer) 推出了针对 COVID-19 的 Paxlovid，并于 2022 年与比尔及梅琳达盖兹基金会 (Bill & Melinda Gates Foundation) 合作，扩大低收入国家获得抗病毒治疗的机会。默克公司 (Merck & Co.) 凭藉用于治疗 COVID-19 的 Molnupiravir 成为头条新闻，并于 2021 年与 Ridgeback Biotherapeutics 合作，加速其开发和分销。吉利德科学公司以 Veklury（瑞德西韦）而闻名，该公司不断创新并扩大其抗病毒产品组合。此外，罗氏控股于2023年收购了抗病毒公司TIB Molbiol，以加强其在病毒诊断和治疗领域的地位。这些公司正在利用合作伙伴关係、收购和合作来增强其抗病毒产品，并满足全球对有效口服抗病毒疗法日益增长的需求。

最新进展：

2021 年 11 月，辉瑞在研的 COVID-19 口服抗病毒药物 PAXLOVID(TM) 在 2/3 期研究中证明，高风险成人的住院或死亡风险降低了 89%。该公司计划很快向 FDA 提交资料以获得紧急使用授权。

2021 年 10 月，默克和 Ridgeback Biotherapeutics 宣布，他们的研究性口服抗病毒药物 molnupiravir 可将轻度至中度 COVID-19 患者的住院或死亡风险降低约 50%。他们计划根据这些结果向 FDA 寻求紧急使用授权。

目录

第一章：口服抗病毒药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按类型分類的口服抗病毒药物市场片段
    • 按给药途径分類的口服抗病毒药物市场片段
    • 口服抗病毒药物市场片段（依应用）
    • 最终用户的口服抗病毒药物市场片段
    • 按国家/地区分類的口服抗病毒药物市场摘要
    • 按地区分類的口服抗病毒药物市场片段
  • 竞争洞察

第 3 章：口服抗病毒药物主要市场趋势

  • 口服抗病毒药物市场驱动因素
    • 市场驱动因素的影响分析
  • 口服抗病毒药物市场限制
    • 市场限制影响分析
  • 口服抗病毒药物市场机会
  • 口服抗病毒药物市场未来趋势

第 4 章：口服抗病毒药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：口服抗病毒药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：口服抗病毒药物市场格局

  • 2023 年口服抗病毒药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：口服抗病毒药物市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 核苷类似物
    • 蛋白酶抑制剂
    • 神经氨酸酶抑制剂
    • 聚合酶抑制剂

第 8 章：口服抗病毒药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 平板电脑
    • 胶囊
    • 口服混悬剂

第 9 章：口服抗病毒药物市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 爱滋病
    • 肝炎
    • 流感
    • 新冠肺炎
    • 疱疹

第 10 章：口服抗病毒药物市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 诊所
    • 家庭护理设置
    • 药局

第 11 章：口服抗病毒药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美口服抗病毒药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲口服抗病毒药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按应用）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区口服抗病毒药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模与预测（按应用）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲口服抗病毒药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按应用）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲口服抗病毒药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按应用）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 口服抗病毒药物产业

  • 竞争仪表板
  • 公司简介
    • AbbVie Inc.
    • Amgen Inc.
    • Aurobindo Pharma Limited
    • BioCryst Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Mylan NV (part of Viatris Inc.)
    • Novartis International AG
    • Pfizer Inc.
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3856

REPORT HIGHLIGHT

Oral Antiviral Market size was valued at USD 37,904.32 Million in 2023, expanding at a CAGR of 2.90% from 2024 to 2032.

The Oral Antiviral Market focuses on medications taken by mouth to treat viral infections, providing an accessible and convenient option for patients. The market is experiencing growth due to the increasing prevalence of viral diseases such as influenza, COVID-19, and herpes simplex. For example, the global market saw a notable rise in oral antiviral treatments with the approval of Paxlovid in 2021, which has been widely utilized for COVID-19 management. However, challenges such as high drug costs and concerns about long-term resistance can impede market growth. Opportunities lie in the development of next-generation oral antivirals with broader efficacy and lower resistance profiles. Additionally, the rising emphasis on personalized medicine and the expansion of healthcare access in emerging markets are contributing to the growth of oral antiviral therapies. The growing number of antiviral drugs in the pipeline and increasing investment in research and development further underscore the market's potential.

Oral Antiviral Market- Market Dynamics

Increasing Prevalence of Viral Diseases Boosts Growth in Oral Antiviral Market

The increasing prevalence of viral diseases is significantly driving the growth of the Oral Antiviral Market. According to the World Health Organization (WHO), influenza and COVID-19 remain major global health concerns, with millions affected annually. The U.S. Centers for Disease Control and Prevention (CDC) reported a surge in antiviral prescriptions during the COVID-19 pandemic, highlighting the critical role of oral antivirals in managing widespread infections. For instance, Paxlovid, an oral antiviral for COVID-19, was prescribed to over 500,000 patients in its first year of availability. Additionally, the rise in chronic viral conditions, such as herpes simplex, has increased the demand for effective oral treatments. As the global focus on combating viral diseases intensifies, advancements in antiviral drug development and expanding access to these medications are crucial factors driving market growth.

Oral Antiviral Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.90% over the forecast period (2024-2032)

Based on Type segmentation, Nucleoside Analogues were predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Tablets was the leading type in 2023

Based on Application segmentation, COVID-19 was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Oral Antiviral Market- Segmentation Analysis:

The Global Oral Antiviral Market is segmented on the basis of Type, Route of Administration, Application, End-User, and Region.

The market is divided into four categories based on Type: Nucleoside Analogues, Protease Inhibitors, Neuraminidase Inhibitors, and Polymerase Inhibitors. Nucleoside analogues lead the market due to their broad efficacy against various viral infections. Protease inhibitors follow, offering targeted action against specific viruses. Neuraminidase inhibitors are significant for influenza treatment, while polymerase inhibitors are crucial but less commonly used.

The market is divided into three categories based on Route of Administration: Tablets, Capsules, and Oral Suspensions. Tablets are the most popular route of administration due to their convenience and dosage accuracy. Capsules follow closely, offering similar benefits with a different format. Oral suspensions are used less frequently but are valuable for patients who have difficulty swallowing tablets or capsules.

Oral Antiviral Market- Geographical Insights

The Oral Antiviral Market shows distinct regional variations, with North America leading due to advanced healthcare systems and high drug adoption rates. In the U.S., the FDA's rapid approval of oral antivirals like Paxlovid during the COVID-19 pandemic led to widespread use, with over 10 million doses administered in the first year. Europe follows closely, where countries such as the UK and Germany have implemented comprehensive antiviral treatment programs, significantly increasing market demand. The European Medicines Agency (EMA) has supported this growth by fast-tracking approvals for new antiviral drugs. In the Asia-Pacific region, countries like Japan and India are experiencing rapid market expansion due to rising viral infection rates and increased healthcare investments. For instance, Japan's Ministry of Health has promoted the use of oral antivirals in managing influenza outbreaks. Latin America and the Middle East & Africa are also growing markets, driven by increasing healthcare infrastructure and rising awareness of antiviral treatments.

Oral Antiviral Market- Competitive Landscape:

The Oral Antiviral Market is competitive, with major players actively engaging in strategic initiatives to maintain their market positions. Pfizer, a leading player, launched Paxlovid for COVID-19 and partnered with the Bill & Melinda Gates Foundation in 2022 to expand access to antiviral treatments in low-income countries. Merck & Co. has made headlines with its Molnupiravir for COVID-19, and in 2021, it collaborated with Ridgeback Biotherapeutics to accelerate its development and distribution. Gilead Sciences, known for Veklury (remdesivir), has continued to innovate and expand its antiviral portfolio. Additionally, Roche Holdings acquired the antiviral company TIB Molbiol in 2023 to strengthen its position in viral diagnostics and treatments. These companies are leveraging partnerships, acquisitions, and collaborations to enhance their antiviral offerings and address the growing global demand for effective oral antiviral therapies.

Recent Developments:

In November 2021, Pfizer's investigational COVID-19 oral antiviral, PAXLOVID(TM), demonstrated an 89% reduction in hospitalization or death risk in high-risk adults during a Phase 2/3 study. The company plans to submit data to the FDA for Emergency Use Authorization soon.

In October 2021, Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral, molnupiravir, reduced the risk of hospitalization or death by about 50% in mild to moderate COVID-19 patients. They plan to seek Emergency Use Authorization from the FDA based on these results.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORAL ANTIVIRAL MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • Aurobindo Pharma Limited
  • BioCryst Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V. (part of Viatris Inc.)
  • Novartis International AG
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ORAL ANTIVIRAL MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Nucleoside Analogues
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors

GLOBAL ORAL ANTIVIRAL MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Tablets
  • Capsules
  • Oral Suspensions

GLOBAL ORAL ANTIVIRAL MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • HIV
  • Hepatitis
  • Influenza
  • COVID-19
  • Herpes

GLOBAL ORAL ANTIVIRAL MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Homecare Settings
  • Pharmacies

GLOBAL ORAL ANTIVIRAL MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Oral Antiviral Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oral Antiviral Market Snippet by Type
    • 2.1.2. Oral Antiviral Market Snippet by Route of Administration
    • 2.1.3. Oral Antiviral Market Snippet by Application
    • 2.1.4. Oral Antiviral Market Snippet by End-User
    • 2.1.5. Oral Antiviral Market Snippet by Country
    • 2.1.6. Oral Antiviral Market Snippet by Region
  • 2.2. Competitive Insights

3. Oral Antiviral Key Market Trends

  • 3.1. Oral Antiviral Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oral Antiviral Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oral Antiviral Market Opportunities
  • 3.4. Oral Antiviral Market Future Trends

4. Oral Antiviral Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oral Antiviral Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Oral Antiviral Market Landscape

  • 6.1. Oral Antiviral Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oral Antiviral Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Nucleoside Analogues
    • 7.1.3. Protease Inhibitors
    • 7.1.4. Neuraminidase Inhibitors
    • 7.1.5. Polymerase Inhibitors

8. Oral Antiviral Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Tablets
    • 8.1.3. Capsules
    • 8.1.4. Oral Suspensions

9. Oral Antiviral Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. HIV
    • 9.1.3. Hepatitis
    • 9.1.4. Influenza
    • 9.1.5. COVID-19
    • 9.1.6. Herpes

10. Oral Antiviral Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Homecare Settings
    • 10.1.5. Pharmacies

11. Oral Antiviral Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Oral Antiviral Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Oral Antiviral Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Oral Antiviral Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Oral Antiviral Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Oral Antiviral Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Oral Antiviral Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. Aurobindo Pharma Limited
    • 12.2.4. BioCryst Pharmaceuticals, Inc.
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Cipla Limited
    • 12.2.7. Dr. Reddy's Laboratories Ltd.
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Johnson & Johnson Services, Inc.
    • 12.2.11. Merck & Co., Inc.
    • 12.2.12. Mylan N.V. (part of Viatris Inc.)
    • 12.2.13. Novartis International AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Roche Holding AG
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us